Compare Summit Therapeutics Inc (SMMT) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs United Microelectronics Corp — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while United Microelectronics Corp trades at $22.96 (market cap $58.02B). The key difference: United Microelectronics Corp is far larger — about 4.2× Summit Therapeutics Inc's market cap, and United Microelectronics Corp pays a 1.76% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and United Microelectronics Corp for 42 Days on average.
| SMMT | UMC | |
|---|---|---|
Market Cap | $13.71B | $58.02B |
Volume | 6,173,057 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $26.38 | $28.02 |
52-Week Low | $12.43 | $7.02 |
Typical Hold Time | 16 Days | 42 Days |
Enterprise Value | $13.04B | $55.10B |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
UMC trades at $22.82, down 2.1% over the past day, with a bullish technical signal but bearish moving averages. The company reported strong recent earnings beats, with Q2 2026 EPS of $0.54 versus $0.16 expected. Revenue for 2025 was $237.55B, with a net income margin of 16.99%. Analyst consensus is mixed, with 26.67% buy ratings and 53.33% hold. Recent news highlights AI-driven growth opportunities and a DCF intrinsic value estimate of $29.
The outlook for UMC is cautiously optimistic, driven by strong earnings performance and expanding AI opportunities. Key risks include competitive pressures in the semiconductor foundry space and potential volatility from AI spending fluctuations. The stock's current valuation metrics, including a P/E of 22.03, suggest room for growth if earnings trends continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
